The market size of US cell-based assays is estimated as USD 3.85 billion in 2025 and is projected to grow by USD 4.18 billion in 2026 to about USD 9.16 billion in 2035 with a CAGR of 9.14% between 2026 and 2035.
US Cell Based Assays Market Revenue and Trends
The cell based assay market in the US offers in vitro assays that rely on living cells to test biological or biochemical activity such as proliferation, cytotoxicity, apoptosis, gene expression, receptor-ligand interactions, and high-content screening, which are mainly used in drug discovery, toxicology, biologics characterization, and basic biomedical research.
The market of US cell based assays is expanding at a fast pace, with more pharmaceutical R&D dollars being spent, more physiologically relevant models and models being sought after, greater uptake of 3D cell culture and organoids, biologics and cell/gene therapy pipelines, and high-throughput screening, label-free technologies and AI-integrated analysis in biopharmaceutical and life sciences ecosystems.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the US cell based assays market?
The increased drug discovery programs, which are motivated by a large drug pipeline, biotech innovation, oncology and wellness attention, and the replacement of animal models by human-relevant in vitro models have driven the demand of cell based assay products. With the growing acceptance of cell-based data by regulatory agencies in submitting INDs and safety evaluations, there will be an increased demand by companies for scalable, reproducible and high-content assay platforms as a means to accelerate lead identification and minimize late stage attrition.
Technological innovations have brought in 3D spheroid/organoid models, CRISPR-edited cell lines, real-time label-free impedance and optical biosensors, multiplexed high-content imaging systems, and AI-driven image/data analysis that has led to increased physiological relevance, throughput, and accuracy of decision-making. Other contributing factors are greater NIH and private board investments into translational research, greater adoption of biologics potency assays and CAR-T characterization, strong regulatory endorsement of alternative approaches (FDA Modernization Act 2.0), and an expansion of academic-industry partnerships and outsourcing to CROs.
Segment Insight
By Product Type
High-content screening (HCS) and high-throughput screening (HTS) cell based assays systems are, as of 2025 by far the largest share of the US cell based assays market, due to their high demand in pharmaceutical drug discovery and lead optimization due to their capability to provide multiparametric data on cellular phenotype, toxicity, and mechanism of action, although further innovation in 3D imaging, automated liquid handling integration, and AI-based hit ranking remains highly exploited, citing large numbers of screening scientists and discovery teams as having found improved means to enhance the hit quality and reduce false positives.
By Distribution Channel
The largest market share comes through direct sales of instruments and reagent suppliers to pharmaceutical/biotech companies and/or academic research institutions that are the main source of buying high-end assay platforms, consumables, custom cell lines, and technical/application support. Because these channels are offering professional expertise in the development of assays, validation, scale-up, and integration with automation systems, they have been the choice to obtain cell based assay technology.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 4.18 billion |
Projected Market Size in 2035 | USD 9.16 billion |
Market Size in 2025 | USD 3.85 billion |
CAGR Growth Rate | 9.14% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Product Type, Application, Technology, End User and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In October 2025: Molecular Devices launched an enhanced ImageXpress® Confocal HT.ai system with next-generation AI-driven analysis modules, enabling faster and more accurate high-content phenotypic profiling in complex 3D cell models for drug discovery and toxicology applications across US pharma and biotech labs.
List of the prominent players in the US Cell-Based Assays Market:
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton Dickinson and Company
Merck KGaA
Lonza Group Ltd.
PerkinElmer Inc.
Bio-Rad Laboratories Inc.
Promega Corporation
Charles River Laboratories
Corning Incorporated
Others
The US Cell-Based Assays Market is segmented as follows:
By Product Type
Consumables
o Reagents
o Assay Kits
o Cell Lines
o Microplates
o Probes & Labels
Instruments
o Flow Cytometers
o High-Content Screening Systems
o Microplate Readers
o Microscopes
Services
o Assay Development Services
o Screening Services
o Consulting Services
By Application
Drug Discovery
o Target Identification & Validation
o Lead Identification & Optimization
o Toxicity Testing
Basic Research
Other Applications
By Technology
Flow Cytometry
High-Content Screening
Label-Free Detection
Other Technologies
By End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
